IL321700A - Salts and solid forms of sonrotoclax intermediate - Google Patents
Salts and solid forms of sonrotoclax intermediateInfo
- Publication number
- IL321700A IL321700A IL321700A IL32170025A IL321700A IL 321700 A IL321700 A IL 321700A IL 321700 A IL321700 A IL 321700A IL 32170025 A IL32170025 A IL 32170025A IL 321700 A IL321700 A IL 321700A
- Authority
- IL
- Israel
- Prior art keywords
- sonrotoclax
- salts
- solid forms
- solid
- forms
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/06—Oxalic acid
- C07C55/07—Salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2022142316 | 2022-12-27 | ||
| PCT/CN2023/141989 WO2024140692A1 (en) | 2022-12-27 | 2023-12-26 | Salts and solid forms of sonrotoclax intermediate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL321700A true IL321700A (en) | 2025-08-01 |
Family
ID=91716479
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL321700A IL321700A (en) | 2022-12-27 | 2023-12-26 | Salts and solid forms of sonrotoclax intermediate |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250320209A1 (en) |
| EP (1) | EP4642776A1 (en) |
| JP (1) | JP2026503230A (en) |
| KR (1) | KR20250127312A (en) |
| CN (1) | CN119301117A (en) |
| AU (1) | AU2023416871A1 (en) |
| IL (1) | IL321700A (en) |
| MX (1) | MX2025007584A (en) |
| TW (1) | TW202434586A (en) |
| WO (1) | WO2024140692A1 (en) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112437772B (en) * | 2018-04-29 | 2023-11-21 | 百济神州有限公司 | Bcl-2 inhibitors |
| WO2021083135A1 (en) * | 2019-10-28 | 2021-05-06 | Beigene, Ltd. | Bcl-2 INHIBITORS |
| WO2021110102A1 (en) * | 2019-12-02 | 2021-06-10 | Beigene, Ltd. | Methods of cancer treatment using bcl-2 inhibitor |
| MX2023014275A (en) * | 2021-06-02 | 2024-03-06 | Beigene Switzerland Gmbh | Methods of treating b-cell malignancy using bcl-2 inhibitor. |
| TW202400163A (en) * | 2022-05-12 | 2024-01-01 | 英屬開曼群島商百濟神州有限公司 | Methods of treating myeloid malignancies using bcl-2 inhibitor |
-
2023
- 2023-12-26 WO PCT/CN2023/141989 patent/WO2024140692A1/en not_active Ceased
- 2023-12-26 EP EP23910615.6A patent/EP4642776A1/en active Pending
- 2023-12-26 IL IL321700A patent/IL321700A/en unknown
- 2023-12-26 AU AU2023416871A patent/AU2023416871A1/en active Pending
- 2023-12-26 TW TW112150831A patent/TW202434586A/en unknown
- 2023-12-26 CN CN202380043279.9A patent/CN119301117A/en active Pending
- 2023-12-26 KR KR1020257024868A patent/KR20250127312A/en active Pending
- 2023-12-26 JP JP2025537587A patent/JP2026503230A/en active Pending
-
2025
- 2025-06-26 US US19/250,670 patent/US20250320209A1/en active Pending
- 2025-06-26 MX MX2025007584A patent/MX2025007584A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202434586A (en) | 2024-09-01 |
| KR20250127312A (en) | 2025-08-26 |
| WO2024140692A1 (en) | 2024-07-04 |
| CN119301117A (en) | 2025-01-10 |
| US20250320209A1 (en) | 2025-10-16 |
| JP2026503230A (en) | 2026-01-28 |
| AU2023416871A1 (en) | 2025-08-14 |
| MX2025007584A (en) | 2025-09-02 |
| EP4642776A1 (en) | 2025-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI4185580T1 (en) | Solid state forms of belumosudil and belumosudil salts | |
| IL288062A (en) | Solid state forms of tafamidis and salts thereof | |
| IL321357A (en) | Inhibitors of kif18a and uses thereof | |
| GB202103594D0 (en) | Antagonist of PCSK9 | |
| IL314320A (en) | Compounds and methods of use | |
| IL304312A (en) | Pharmaceutically acceptable salts of psilocin and uses thereof | |
| IL318393A (en) | Aza-quinazoline compounds and methods of use | |
| IL316654A (en) | Preparation and uses of 7-azaindenoisoquinolines | |
| GB202411655D0 (en) | Application of circHIF1a | |
| GB202401487D0 (en) | Salts and polymorphs of mitragynine and 3-deuteromitragynine | |
| IL314277A (en) | Anti-b7-h3 compounds and methods of use | |
| IL314594A (en) | Heterocyclic compounds and methods of use | |
| IL326152A (en) | Solid state forms of gusacitinib | |
| PL4441028T3 (en) | Salt of s-oxprenolol | |
| HK40128909A (en) | Salts and solid forms of sonrotoclax intermediate | |
| CA3277370A1 (en) | Salts and solid forms of sonrotoclax intermediate | |
| LT4027976T (en) | Rifabutin compositions and method of making | |
| IL312041A (en) | R-ketamine salts and methods of use thereof | |
| GB202316444D0 (en) | Salts of opicapone | |
| IL319769A (en) | Solid state forms of mesdopetam and salts therofsolid state forms of mesdopetam and salts therof | |
| CA3279207A1 (en) | Solid state forms of brilaroxazine and brilaroxazine salts | |
| IL326153A (en) | Solid state forms of gusacitinib | |
| IL319179A (en) | Solid state forms of denifanstat | |
| GB202215264D0 (en) | Use of urolithins | |
| GB202315697D0 (en) | Compounds and methods of use |